Neurocrine and Wyeth extended their research agreement for a further year to discover, develop and commercialize compounds that modulate excitatory amino acid transporters for treating neurodegenerative and psychiatric diseases. Neurocrine will access Wyeth’s chemical libraries for screening using its technology.